Renal injury induced by lenvatinib in advanced hepatocellular carcinoma treated with multi- drug combination: a case report and literature review
10.3760/cma.j.cn441217-20221006-01006
- VernacularTitle:多药联合治疗晚期原发性肝癌中的仑伐替尼致肾损害1例及文献复习
- Author:
Ju HUANG
1
;
Wei YE
;
Yubing WEN
;
Ke ZHENG
Author Information
1. 中国医学科学院 北京协和医学院，北京 100730
- Keywords:
Antineoplastic agents;
Carcinoma, hepatocellular;
Kidney diseases;
Lenvatinib
- From:
Chinese Journal of Nephrology
2023;39(8):616-619
- CountryChina
- Language:Chinese
-
Abstract:
The article reported one case of renal damage caused by lenvatinib in the treatment of advanced primary liver cancer. The patient was a 63-year-old male who was admitted to the hospital due to "liver cancer for 4 years, blood pressure elevation for nearly 2 years, and edema for 7 months". During the treatment of liver tumors with atezolizumab combined with lenvatinib, blood pressure increased and renal insufficiency aggravated progressively. Pathological light microscopy of renal biopsy showed endothelial cell lesion and tubulointerstitial damage, and electron microscopy showed moderate proliferation of mesangial cells and deposition of mesangial matrix. There were many agglomerated low-electron density deposits in the mesangial area, and a small amount of electron dense deposits in the subendothelium. The pathological diagnosis was endothelial cell disease (thrombotic microangiopathy) and secondary focal segmental glomerulosclerosis. Renal injury was considered as secondary to lenvatinib. After discontinuing lenvatinib and giving angiotensin receptor antagonist treatment, blood pressure was normal, urine protein turned negative, and renal function improved significantly after 8 months of outpatient follow-up.
